A thorough understanding of post-inspection procedures and potential actions can reduce the likelihood of additional enforcement against manufacturers including seizures, injunctions, litigation, and criminal prosecution. This webinar will enumerate what to expect after an FDA inspection; distinguish FDA post-inspection notices, such as 483 forms, warning letters, and close-out letters; discuss best practices to effectively communicate with FDA and demonstrate accountability to shareholders and consumers; and provide key tips for avoiding the most serious enforcement actions.

Get Access

  • +$100 for nonmembers

Internet Explorer and Microsoft Edge are not supported by the checkout process.

Please use Chrome, Firefox, or Safari.  If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.


Hannah R. Bornstein, Partner, Nixon Peabody LLP
Teresa Gorecki, Practice Director, Compliance Architects LLC
Stephanie M. Haggerty, Senior Corporate Counsel, Pfizer
Beth P. Weinman, Counsel, Ropes & Gray LLP
Moderated by Maya P. Florence, Partner, Skadden, Arps, Slate, Meagher & Flom LLP

Virtual Learning FAQ

On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.


On-demand content can be played back on most devices.


CLE credit is not currently available for pre-recorded sessions.

Related Content